Translational Neuroinflammation

The aim of the Translational Neuroinflammation group is to develop new therapeutic approaches for largely intractable diseases of the central nervous system (CNS), such as progressive multiple sclerosis (MS). The mode of action of potential treatment candidates will be investigated in vitro in cell culture models using murine and human CNS-resident cells.

Furthermore, the clinical benefit will be evaluated using appropriate in vivo models, such as experimental autoimmune encephalomyelitis (EAE) and the Cuprizone model.

The findings from the experimental research will be transferred to the Early Clinical Trial Unit for testing on patients in order to create a basis for innovations in prevention, diagnostics and new therapies.